

Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease: a prospective cohort study

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is associated with a higher risk of all-cause and cause-specific morbidity and mortality.¹⁻³ Animal studies suggest that air pollution may play a role in the development of NAFLD.^{4,5} However, evidence from human studies is limited.⁶

Here, we prospectively estimated the association between long-term exposure to fine particulate matter (PM_{2.5}) and risk of NAFLD in 58 026 Taiwan residents who received a standard medical screening programme between 2001 and 2016. We excluded participants with (a) missing values of covariates; (b) excess alcohol intake; (c) liver disease at baseline; (d) NAFLD at baseline and (e) only one medical examination (online supplemental figure S1). The final analytic sample included 35 614 participants for fatty liver index (FLI)-based cohort and 34 741 participants for hepatic steatosis index (HSI)-based cohort. We defined the incident NAFLD as the first occurrence of values of FLI > 30 or HSI > 36, which have been validated in the Asian population.^{7,8} We estimated annual PM_{2.5} levels at participants' residential addresses using multiple satellite-based aerosol optical

Table 1 Association between long-term exposure to fine particulate matter (PM_{2.5}) and risk of non-alcoholic fatty liver disease in Taiwanese population

Exposure	Number of events	Minimally adjusted model* HR (95% CI)	Partially adjusted model† HR (95% CI)	Fully adjusted model‡ HR (95% CI)
Outcome for fatty liver index (FLI)				
First quartile (median 14.5 µg/m ³)	1738	Reference	Reference	Reference
Second quartile (median 22.0 µg/m ³)	1262	1.02 (0.95 to 1.10)	1.00 (0.93 to 1.08)	1.00 (0.93 to 1.08)
Third quartile (median 25.0 µg/m ³)	1809	1.03 (0.96 to 1.10)	1.03 (0.96 to 1.10)	1.03 (0.96 to 1.10)
Fourth quartile (median 27.5 µg/m ³)	2064	1.30 (1.21 to 1.40)	1.34 (1.25 to 1.44)	1.34 (1.25 to 1.44)
P for trend		<0.001	<0.001	<0.001
Continuous per 1 µg/m ³ increase in PM _{2.5} (>breakpoint§)	6873	1.06 (1.03 to 1.08)	1.07 (1.04 to 1.09)	1.06 (1.04 to 1.08)
Outcome for hepatic steatosis index (HSI)				
First quartile (median 14.5 µg/m ³)	1905	Reference	Reference	Reference
Second quartile (median 22.0 µg/m ³)	1332	0.98 (0.91 to 1.05)	0.99 (0.92 to 1.06)	0.99 (0.92 to 1.06)
Third quartile (median 25.0 µg/m ³)	2031	1.02 (0.96 to 1.09)	1.04 (0.97 to 1.10)	1.03 (0.97 to 1.10)
Fourth quartile (median 27.5 µg/m ³)	2391	1.20 (1.12 to 1.28)	1.20 (1.12 to 1.29)	1.20 (1.12 to 1.28)
P for trend		<0.001	<0.001	<0.001
Continuous per 1 µg/m ³ increase in PM _{2.5} (>breakpoint¶)	7659	1.07 (1.05 to 1.09)	1.06 (1.04 to 1.08)	1.06 (1.04 to 1.07)

*Models were adjusted for age and year of enrolment.

†Models were additionally adjusted for season of measurement, gender, smoking status, alcohol consumption, occupational exposure, educational attainment, vegetable intake, fruit intake, sugar drink intake, fried food intake, habitual physical activity, and physical activity at work. HSI takes gender into account, so we did not adjust for it in the models.

‡Models were additionally adjusted for cancer, long-term use of hyperlipidemia drugs, cardiovascular disease, and hypertension.

§Breakpoints of PM_{2.5} exposure were identified by using piecewise Cox proportional hazards regression with 'Segmented' R package. The breakpoints of FLI for minimally, partially and fully adjusted models were 23.4 µg/m³, 23.5 µg/m³ and 23.5 µg/m³, respectively.

¶Breakpoints of PM_{2.5} exposure were identified by using piecewise Cox proportional hazards regression with 'Segmented' R package. Breakpoints of HSI for minimally, partially and fully adjusted models were 23.8 µg/m³, 23.6 µg/m³ and 23.5 µg/m³, respectively.

depth data combined with a chemical transport model.⁹ Physical examinations were conducted by trained technicians using a standardised protocol. Demographic characteristics and lifestyle data were collected using a standard self-administered questionnaire. We used time-varying Cox proportional hazards models to estimate HRs of the association between continuous and categorical PM_{2.5} estimates and risk of

NAFLD. We conducted stratified analyses to identify vulnerable populations.

We documented 6873 incidence of FLI-defined NAFLD and 7659 incidence of HSI-defined NAFLD during the study period. Risks of NAFLD were associated with PM_{2.5} at concentrations above 23.5 µg/m³; each 1 µg/m³ increase in PM_{2.5} was associated with an HR of 1.06 (95% CI: 1.04 to 1.08) for FLI-defined NAFLD and an HR of 1.06 (95% CI: 1.04 to 1.07) for HSI-defined NAFLD. Those living in the highest quartile of PM_{2.5} had a 34% higher rate of FLI-defined NAFLD (95% CI: 1.25 to 1.44) and a 20% higher rate of HSI-defined NAFLD (95% CI: 1.12 to 1.28) than those in the lowest quartile (table 1). Our results were not materially different in sensitivity analyses adjusting for metabolic syndrome, restricting analyses among never drinkers, or using concentrations of PM_{2.5} at the previous year of the medical measurement as a proxy for air pollution exposure (online supplemental tables S1-S3). The association was more pronounced among physically inactive participants, but we found no evidence of effect modification by other personal characteristics (figure 1).

To our knowledge, this is the first prospective cohort study to examine the association between long-term PM_{2.5} exposure and risk of NAFLD. Our findings are consistent with an analysis among 2513 participants from the Framingham (Massachusetts) Offspring Study and Third Generation Cohort,⁶ the only study so far that directly examined the association between long-term exposure




Figure 1 The HRs of non-alcoholic fatty liver disease associated with fine particulate matter above 23.5 µg/m³ with each 1 µg/m³ increase in fine particulate matter by personal characteristics. P value for effect modification was tested using two-sample Z test. Squares in orange represent the risk estimates are statistically significant. CI, confidence interval; PA, physical activity.

to PM_{2.5} and risk of hepatic steatosis. This study found that living closer to a major roadway was associated with more liver fat and higher prevalence of hepatic steatosis.⁶ Our findings were also consistent with the evidence from animal studies,^{4,5} which showed that exposure to PM_{2.5} was associated with higher levels of hepatic steatosis and fibrosis compared with exposure to filtered air in mice. Underlying mechanisms linking PM_{2.5} exposure with NAFLD are that particulate matter may promote hepatic steatosis through inflammation, oxidative stress, insulin resistance and specific molecular and metabolic derangements.¹⁰

In conclusion, long-term exposure to ambient PM_{2.5} was associated with a higher risk of NAFLD at relatively higher concentrations. Given that the majority of evidence of association between PM_{2.5} and NAFLD was from animal studies, our findings substantially extended the existing evidence that air pollution is potentially a novel risk factor for the development of human NAFLD.

Shengzhi Sun ^{1,2} Qingqing Yang,¹
Qingxin Zhou,¹ Wangnan Cao ^{3,4} Siwang Yu,⁵
Siyan Zhan,¹ Feng Sun ¹

¹Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China

²Department of Environmental Health, School of Public Health, Boston University, Boston, Massachusetts, USA

³Department of Social Medicine and Health Education, School of Public Health, Peking University, Beijing, China

⁴Center for Evidence Synthesis in Health, School of Public Health, Brown University, Providence, Rhode Island, USA

⁵Department of Molecular and Cellular Pharmacology, Peking University School of Pharmaceutical Sciences, Beijing, China

Correspondence to Dr Feng Sun, Department of Epidemiology and Biostatistics, Peking University Health Science Center, Beijing 100191, China; sunfeng@bjmu.edu.cn

Correction notice This article has been corrected since it published Online First. A typographical error has been corrected in table 1.

Acknowledgements The authors thank MJ Health Research Foundation for authorisation of using MJ health data (authorisation code: MJHRF2019010A). Any interpretation or conclusion described in this article does not represent the views of MJ Health Research Foundation. The authors are grateful to Amruta Nori-Sarma for helpful discussions.

Contributors SS and QY analysed the data, drafted the manuscript and are the guarantors. SZ and FS designed, revised and supervised the study. All authors revised the manuscript and approved the final draft.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Ethical approval for this study was obtained from the Ethics committee of the Peking University Health Science Center (No. IRB00001052-20026).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2021-324364>).

SS and QY contributed equally.



To cite Sun S, Yang Q, Zhou Q, *et al.* Gut Epub ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2021-324364

Received 8 February 2021

Revised 7 March 2021

Accepted 18 March 2021

Gut 2021;0:1–2. doi:10.1136/gutjnl-2021-324364

ORCID iDs

Shengzhi Sun <http://orcid.org/0000-0002-3708-1225>

Wangnan Cao <http://orcid.org/0000-0002-6163-2760>

Feng Sun <http://orcid.org/0000-0003-4334-6805>

REFERENCES

- Simon TG, Roelstraete B, Khalili H, *et al.* Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. *Gut* 2020. doi:10.1136/gutjnl-2020-322786. [Epub ahead of print: 09 Oct 2020].
- Mantovani A, Petracca G, Beatrice G, *et al.* Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. *Gut* 2020. doi:10.1136/gutjnl-2020-322572. [Epub ahead of print: 16 Sep 2020].
- Mantovani A, Petracca G, Beatrice G, *et al.* Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. *Gut* 2020. doi:10.1136/gutjnl-2020-323082. [Epub ahead of print: 10 Dec 2020].
- Tan H-H, Fiel MI, Sun Q, *et al.* Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. *J Immunotoxicol* 2009;6:266–75.
- Zheng Z, Xu X, Zhang X, *et al.* Exposure to ambient particulate matter induces a NASH-like phenotype and impairs hepatic glucose metabolism in an animal model. *J Hepatol* 2013;58:148–54.
- Li W, Dorans KS, Wilker EH, *et al.* Residential proximity to major roadways, fine particulate matter, and hepatic steatosis: the Framingham heart study. *Am J Epidemiol* 2017;186:857–65.
- Zhu J, He M, Zhang Y, *et al.* Validation of simple indexes for nonalcoholic fatty liver disease in Western China: a retrospective cross-sectional study. *Endocr J* 2018;65:373–81.
- Lee J-H, Kim D, Kim HJ, *et al.* Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. *Dig Liver Dis* 2010;42:503–8.
- van Donkelaar A, Martin RV, Brauer M, *et al.* Global estimates of fine particulate matter using a combined geophysical-statistical method with information from satellites, models, and monitors. *Environ Sci Technol* 2016;50:3762–72.
- Arciello M, Gori M, Maggio R, *et al.* Environmental pollution: a tangible risk for NAFLD pathogenesis. *Int J Mol Sci* 2013;14:22052–66.

Supplementary Material

Long-term Exposure to Fine Particulate Matter and Non-alcoholic Fatty Liver Disease: A Prospective Cohort Study

Table of Content

Table S1. Association between long-term exposure to fine particulate matter and risk of non-alcoholic fatty liver disease additionally adjusted for metabolic syndrome among Taiwan residents.

Table S2. Association between long-term exposure to fine particulate matter and risk of non-alcoholic fatty liver disease among never drinkers.

Table S3. Association between long-term exposure to fine particulate matter at the previous year of the medical measurement and risk of non-alcoholic fatty liver disease among Taiwan residents.

Figure S1. Flow chart of the study population.

Table S1. Association between long-term exposure to fine particulate matter and risk of non-alcoholic fatty liver disease with additionally adjusted for metabolic syndrome among Taiwan residents*.

Exposure	Number of events	Main model [†] HR (95% CI)	Additionally adjusted for metabolic syndrome HR (95% CI)
Fatty liver index (FLI)			
1 st Quartile (median 14.5 µg/m ³)	1,738	Reference	Reference
2 nd Quartile (median 22.0 µg/m ³)	1,262	1.00 (0.93, 1.08)	0.99 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	1,809	1.03 (0.96, 1.10)	1.02 (0.95, 1.10)
4 th Quartile (median 27.5 µg/m ³)	2,064	1.34 (1.25, 1.44)	1.35 (1.25, 1.45)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [‡])	6,873	1.06 (1.04, 1.08)	1.06 (1.04, 1.08)
Hepatic steatosis index (HSI)			
1 st Quartile (median 14.5 µg/m ³)	1,905	Reference	Reference
2 nd Quartile (median 22.0 µg/m ³)	1,332	0.99 (0.92, 1.06)	1.00 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	2,031	1.03 (0.97, 1.10)	1.05 (0.99, 1.13)
4 th Quartile (median 27.5 µg/m ³)	2,391	1.20 (1.12, 1.28)	1.20 (1.12, 1.28)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [§])	7,659	1.06 (1.04, 1.07)	1.06 (1.04, 1.07)

Abbreviations: HR=hazard ratio; CI=confidence interval.

*Metabolic syndrome was defined by the NCEP ATP III modified for Asian's criteria.

[†]Models were adjusted for age, year of enrollment, season of measurement, gender, smoking status, alcohol consumption, occupational exposure, educational attainment, vegetable intake, fruit intake, sugar drink, fried food intake, habitual physical activity, physical activity at work, cancer, long-term use of hyperlipidemia drugs, cardiovascular disease, and hypertension. HSI takes gender into account, we did not adjust for it in the models.

[‡]Breakpoints of FLI for minimally, partially, and fully adjusted models were 23.4µg/m³, and 23.5µg/m³ respectively.

[§]Breakpoints of HSI for minimally, partially, and fully adjusted models were 23.8µg/m³, and 23.6µg/m³ respectively.

Table S2. Association between long-term exposure to fine particulate matter and risk of non-alcoholic fatty liver disease among never drinkers.

Exposure	Number of events	Minimally adjusted model* HR (95% CI)	Fully adjusted model† HR (95% CI)
Fatty liver index (FLI)			
1 st Quartile (median 15.0 µg/m ³)	1,550	Reference	Reference
2 nd Quartile (median 22.0 µg/m ³)	1,110	1.01 (0.93, 1.09)	0.99 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	1,597	1.02 (0.95, 1.10)	1.02 (0.95, 1.10)
4 th Quartile (median 27.5 µg/m ³)	1,849	1.32 (1.22, 1.42)	1.35 (1.25, 1.45)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [‡])	6,106	1.06 (1.04, 1.08)	1.06 (1.04, 1.09)
Hepatic steatosis index (HSI)			
1 st Quartile (median 14.5 µg/m ³)	1,723	Reference	Reference
2 nd Quartile (median 22.0 µg/m ³)	1,216	0.99 (0.92, 1.06)	1.00 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	1,867	1.04 (0.98, 1.11)	1.05 (0.99, 1.13)
4 th Quartile (median 27.5 µg/m ³)	2,183	1.19 (1.12, 1.28)	1.20 (1.12, 1.28)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [§])	6,989	1.08 (1.06, 1.10)	1.06 (1.04, 1.08)

Abbreviations: HR=hazard ratio; CI=confidence interval.

*Models were adjusted for age, and year of enrollment.

†Models were additionally adjusted for season of measurement, gender, smoking status, alcohol consumption, occupational exposure, educational attainment, vegetable intake, fruit intake, sugar drink, fried food intake, habitual physical activity, physical activity at work, cancer, long-term use of hyperlipidemia drugs, cardiovascular disease, and hypertension. HSI takes gender into account, we did not adjust for it in the models.

[‡]Breakpoints of FLI for minimally and fully adjusted models were 23.5µg/m³ and 23.6µg/m³ respectively.

[§]Breakpoints of HSI for minimally and fully adjusted models were 23.7µg/m³ and 23.6µg/m³ respectively.

Table S3. Association between long-term exposure to fine particulate matter at the previous year of the medical measurement and risk of non-alcoholic fatty liver disease among Taiwan residents.

Exposure	Number of events	Minimally adjusted model* HR (95% CI)	Fully adjusted model† HR (95% CI)
Fatty liver index (FLI)			
1 st Quartile (median 13.0 µg/m ³)	1,434	Reference	Reference
2 nd Quartile (median 21.0 µg/m ³)	1,499	0.98 (0.92, 1.06)	0.99 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	1,375	1.13 (1.05, 1.21)	1.14 (1.06, 1.23)
4 th Quartile (median 28.0 µg/m ³)	2,565	1.13 (1.06, 1.21)	1.16 (1.08, 1.24)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [‡])	6,873	1.06 (1.03, 1.08)	1.06 (1.04, 1.08)
Hepatic steatosis index (HSI)			
1 st Quartile (median 13.0 µg/m ³)	1,599	Reference	Reference
2 nd Quartile (median 21.0 µg/m ³)	1,607	0.93 (0.87, 1.00)	0.94 (0.87, 1.00)
3 rd Quartile (median 25.0 µg/m ³)	1,477	1.03 (0.96, 1.10)	1.04 (0.97, 1.11)
4 th Quartile (median 28.0 µg/m ³)	2,976	1.08 (1.00, 1.15)	1.08 (1.02, 1.15)
<i>p</i> for trend		0.010	0.005
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [§])	7,659	1.07 (1.05, 1.09)	1.06 (1.04, 1.07)

Abbreviations: HR=hazard ratio; CI=confidence interval.


*Models were adjusted for age, and year of enrollment.

†Models were additionally adjusted for season of measurement, gender, smoking status, alcohol consumption, occupational exposure, educational attainment, vegetable intake, fruit intake, sugar drink, fried food intake, habitual physical activity, physical activity at work, cancer, long-term use of hyperlipidemia drugs, cardiovascular disease, and hypertension. HSI takes gender into account, we did not adjust for it in the models.

[‡]Breakpoints of FLI for minimally and fully adjusted models were 23.5µg/m³ and 23.5µg/m³ respectively.

[§]Breakpoints of HSI for minimally and fully adjusted models were 23.8µg/m³ and 23.5µg/m³ respectively.

Figure S1. Flow chart of the study population. NALFD=nonalcoholic fatty liver disease, PM_{2.5}=fine particulate matter, FLI=fatty liver index, HSI= hepatic steatosis index, ALT= Alanine aminotransferase test; AST= Aspartate aminotransferase test; GGT= Gamma-glutamyl transferase.



Supplementary Material

Long-term Exposure to Fine Particulate Matter and Non-alcoholic Fatty Liver Disease: A Prospective Cohort Study

Table of Content

Table S1. Association between long-term exposure to fine particulate matter and risk of non-alcoholic fatty liver disease additionally adjusted for metabolic syndrome among Taiwan residents.

Table S2. Association between long-term exposure to fine particulate matter and risk of non-alcoholic fatty liver disease among never drinkers.

Table S3. Association between long-term exposure to fine particulate matter at the previous year of the medical measurement and risk of non-alcoholic fatty liver disease among Taiwan residents.

Figure S1. Flow chart of the study population.

Table S1. Association between long-term exposure to fine particulate matter and risk of non-alcoholic fatty liver disease with additionally adjusted for metabolic syndrome among Taiwan residents*.

Exposure	Number of events	Main model [†] HR (95% CI)	Additionally adjusted for metabolic syndrome HR (95% CI)
Fatty liver index (FLI)			
1 st Quartile (median 14.5 µg/m ³)	1,738	Reference	Reference
2 nd Quartile (median 22.0 µg/m ³)	1,262	1.00 (0.93, 1.08)	0.99 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	1,809	1.03 (0.96, 1.10)	1.02 (0.95, 1.10)
4 th Quartile (median 27.5 µg/m ³)	2,064	1.34 (1.25, 1.44)	1.35 (1.25, 1.45)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [‡])	6,873	1.06 (1.04, 1.08)	1.06 (1.04, 1.08)
Hepatic steatosis index (HSI)			
1 st Quartile (median 14.5 µg/m ³)	1,905	Reference	Reference
2 nd Quartile (median 22.0 µg/m ³)	1,332	0.99 (0.92, 1.06)	1.00 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	2,031	1.03 (0.97, 1.10)	1.05 (0.99, 1.13)
4 th Quartile (median 27.5 µg/m ³)	2,391	1.20 (1.12, 1.28)	1.20 (1.12, 1.28)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [§])	7,659	1.06 (1.04, 1.07)	1.06 (1.04, 1.07)

Abbreviations: HR=hazard ratio; CI=confidence interval.

*Metabolic syndrome was defined by the NCEP ATP III modified for Asian's criteria.

[†]Models were adjusted for age, year of enrollment, season of measurement, gender, smoking status, alcohol consumption, occupational exposure, educational attainment, vegetable intake, fruit intake, sugar drink, fried food intake, habitual physical activity, physical activity at work, cancer, long-term use of hyperlipidemia drugs, cardiovascular disease, and hypertension. HSI takes gender into account, we did not adjust for it in the models.

[‡]Breakpoints of FLI for minimally, partially, and fully adjusted models were 23.4µg/m³, and 23.5µg/m³ respectively.

[§]Breakpoints of HSI for minimally, partially, and fully adjusted models were 23.8µg/m³, and 23.6µg/m³ respectively.

Table S2. Association between long-term exposure to fine particulate matter and risk of non-alcoholic fatty liver disease among never drinkers.

Exposure	Number of events	Minimally adjusted model* HR (95% CI)	Fully adjusted model† HR (95% CI)
Fatty liver index (FLI)			
1 st Quartile (median 15.0 µg/m ³)	1,550	Reference	Reference
2 nd Quartile (median 22.0 µg/m ³)	1,110	1.01 (0.93, 1.09)	0.99 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	1,597	1.02 (0.95, 1.10)	1.02 (0.95, 1.10)
4 th Quartile (median 27.5 µg/m ³)	1,849	1.32 (1.22, 1.42)	1.35 (1.25, 1.45)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint‡)	6,106	1.06 (1.04, 1.08)	1.06 (1.04, 1.09)
Hepatic steatosis index (HSI)			
1 st Quartile (median 14.5 µg/m ³)	1,723	Reference	Reference
2 nd Quartile (median 22.0 µg/m ³)	1,216	0.99 (0.92, 1.06)	1.00 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	1,867	1.04 (0.98, 1.11)	1.05 (0.99, 1.13)
4 th Quartile (median 27.5 µg/m ³)	2,183	1.19 (1.12, 1.28)	1.20 (1.12, 1.28)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint§)	6,989	1.08 (1.06, 1.10)	1.06 (1.04, 1.08)

Abbreviations: HR=hazard ratio; CI=confidence interval.

*Models were adjusted for age, and year of enrollment.

†Models were additionally adjusted for season of measurement, gender, smoking status, alcohol consumption, occupational exposure, educational attainment, vegetable intake, fruit intake, sugar drink, fried food intake, habitual physical activity, physical activity at work, cancer, long-term use of hyperlipidemia drugs, cardiovascular disease, and hypertension. HSI takes gender into account, we did not adjust for it in the models.

‡Breakpoints of FLI for minimally and fully adjusted models were 23.5µg/m³ and 23.6µg/m³ respectively.

§Breakpoints of HSI for minimally and fully adjusted models were 23.7µg/m³ and 23.6µg/m³ respectively.

Table S3. Association between long-term exposure to fine particulate matter at the previous year of the medical measurement and risk of non-alcoholic fatty liver disease among Taiwan residents.

Exposure	Number of events	Minimally adjusted model* HR (95% CI)	Fully adjusted model† HR (95% CI)
Fatty liver index (FLI)			
1 st Quartile (median 13.0 µg/m ³)	1,434	Reference	Reference
2 nd Quartile (median 21.0 µg/m ³)	1,499	0.98 (0.92, 1.06)	0.99 (0.92, 1.07)
3 rd Quartile (median 25.0 µg/m ³)	1,375	1.13 (1.05, 1.21)	1.14 (1.06, 1.23)
4 th Quartile (median 28.0 µg/m ³)	2,565	1.13 (1.06, 1.21)	1.16 (1.08, 1.24)
<i>p</i> for trend		<0.001	<0.001
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [‡])	6,873	1.06 (1.03, 1.08)	1.06 (1.04, 1.08)
Hepatic steatosis index (HSI)			
1 st Quartile (median 13.0 µg/m ³)	1,599	Reference	Reference
2 nd Quartile (median 21.0 µg/m ³)	1,607	0.93 (0.87, 1.00)	0.94 (0.87, 1.00)
3 rd Quartile (median 25.0 µg/m ³)	1,477	1.03 (0.96, 1.10)	1.04 (0.97, 1.11)
4 th Quartile (median 28.0 µg/m ³)	2,976	1.08 (1.00, 1.15)	1.08 (1.02, 1.15)
<i>p</i> for trend		0.010	0.005
Continuous per 1µg/m ³ increase in PM _{2.5} (>breakpoint [§])	7,659	1.07 (1.05, 1.09)	1.06 (1.04, 1.07)

Abbreviations: HR=hazard ratio; CI=confidence interval.

*Models were adjusted for age, and year of enrollment.

†Models were additionally adjusted for season of measurement, gender, smoking status, alcohol consumption, occupational exposure, educational attainment, vegetable intake, fruit intake, sugar drink, fried food intake, habitual physical activity, physical activity at work, cancer, long-term use of hyperlipidemia drugs, cardiovascular disease, and hypertension. HSI takes gender into account, we did not adjust for it in the models.

‡Breakpoints of FLI for minimally and fully adjusted models were 23.5µg/m³ and 23.5µg/m³ respectively.

§Breakpoints of HSI for minimally and fully adjusted models were 23.8µg/m³ and 23.5µg/m³ respectively.

Figure S1. Flow chart of the study population. NALFD=nonalcoholic fatty liver disease, PM_{2.5}=fine particulate matter, FLI=fatty liver index, HSI= hepatic steatosis index, ALT= Alanine aminotransferase test; AST= Aspartate aminotransferase test; GGT= Gamma-glutamyl transferase.

